ImmunityBio, Inc. IBRX Reportable Segment — Operating Expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s reportable segment — operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s reportable segment — operating expenses?
- ImmunityBio, Inc. (IBRX) reported reportable segment — operating expenses of $113.76M in Q1 2026.
- How has ImmunityBio, Inc.'s reportable segment — operating expenses changed year-over-year?
- ImmunityBio, Inc.'s reportable segment — operating expenses increased by 40.6% year-over-year, from $80.89M to $113.76M.
- What is the long-term trend for ImmunityBio, Inc.'s reportable segment — operating expenses?
- Over 2 years (2023 to 2025), ImmunityBio, Inc.'s reportable segment — operating expenses has grown at a 0.8% compound annual growth rate (CAGR), from $362.87M to $368.56M.
- What does reportable segment — operating expenses mean?
- Represents the total costs incurred by a specific business segment to support its primary research, development, and administrative activities. This metric captures the operational burn rate required to advance clinical-stage biotechnology programs toward commercialization.